Provider Briefing: Afrezza Availability in 2026

If you prescribe Afrezza 180 Titration Pack- 60, 60, 60, you've likely heard from patients who can't find it at their pharmacy. This article provides a concise overview of the current supply situation, prescribing implications, and tools you can use to help your patients maintain access to inhaled insulin therapy.

Current Supply Status

MannKind Corporation continues to manufacture Afrezza, and the product has not been discontinued. However, intermittent availability issues persist across many regions. These are driven primarily by:

• Single-source manufacturing: MannKind is the sole manufacturer. Any production variability directly impacts national supply.
• Limited retail pharmacy stocking: Most chain pharmacies do not routinely stock Afrezza due to low prescription volume. The product often requires special ordering.
• Specialty distribution channels: Afrezza is frequently distributed through specialty pharmacies rather than traditional wholesale networks, limiting point-of-sale access.

Timeline of Supply Challenges

Afrezza has faced periodic availability constraints since its initial FDA approval in 2014. The product's unique delivery system — requiring both single-use cartridges and a proprietary inhaler replaced every 15 days — introduces supply chain complexity not seen with conventional insulin products. MannKind has scaled production capacity over time, but demand patterns remain difficult to predict given the relatively small patient population.

Prescribing Implications

When prescribing or maintaining patients on Afrezza, consider the following:

• Verify pharmacy availability before prescribing. Consider directing patients to specialty pharmacies or using tools like Medfinder for Providers to identify pharmacies with current stock.
• Ensure spirometry is current. FEV1 testing is required before initiation and should be monitored periodically. Patients with any history of chronic lung disease (asthma, COPD) remain contraindicated.
• Have a contingency plan. Given supply variability, it's prudent to discuss backup rapid-acting insulin options (insulin lispro, insulin aspart, or Fiasp) with patients at the time of prescribing.
• Document medical necessity. Many payers require prior authorization for Afrezza. Thorough documentation of why inhaled insulin is preferred (e.g., needle phobia, injection site issues, adherence concerns with injectable insulin) supports approval.

Availability and Access Strategies

Several approaches can improve your patients' access to Afrezza:

1. Specialty pharmacy referral: Identify one or two specialty pharmacies in your area that reliably stock Afrezza and direct patients accordingly.
2. Mail-order specialty pharmacy: Many insurers have preferred specialty mail-order pharmacies that carry Afrezza. This removes geographic availability barriers.
3. MannKind's AfrezzaAssist program: This manufacturer-sponsored program provides access support, co-pay assistance, and pharmacy identification services. Information is available at afrezza.com/savings-program.
4. Medfinder for Providers: medfinder.com/providers offers real-time pharmacy inventory data, allowing your staff to verify availability before sending a prescription.

Cost and Coverage Considerations

The average cash price for Afrezza is approximately $550 to $650 per prescription, depending on the specific pack. Key coverage notes:

• Most commercial plans place Afrezza on a specialty or non-preferred brand tier, resulting in higher patient cost-sharing.
• Prior authorization is commonly required. Step therapy (requiring failure on injectable insulin) may apply.
• Medicare Part D plans vary significantly in Afrezza coverage. Some plans cover it; others exclude it entirely.
• Discount card programs (SingleCare, GoodRx) may provide modest savings for cash-pay patients.

For detailed savings strategies to share with patients, see our patient savings guide.

Tools for Your Practice

Consider integrating these resources into your workflow:

• Medfinder for Providers: Real-time medication availability search. Share with patients or use at the point of prescribing.
• AfrezzaAssist: Manufacturer support for access, coverage, and affordability.
• Prior authorization templates: Prepare standard documentation for Afrezza prior auth requests, including clinical rationale for inhaled insulin over injectable alternatives.

Final Thoughts

Afrezza remains a clinically valuable option for the right patient — particularly those with needle aversion, injection fatigue, or suboptimal adherence on injectable mealtime insulin. The supply situation requires proactive management, but with the right tools and pharmacy relationships, most patients can maintain access.

For the patient-facing version of this update, see our patient shortage update. For guidance on helping patients locate Afrezza, visit our provider's guide to finding Afrezza.